Sekonder Profilaksi Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör

de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. out-of-hospital cardiac arrest in the 1990’s: a population-based study in the maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30:1500–5.

Lynge TH, Risgaard B, Banner J, et al. Nationwide burden of sudden cardiac death: a study of 54,028 deaths in Denmark. Heart Rhythm 2021;18:1657–65.

Moss AJ, Hall WJ, Cannom DS,et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996 Dec 26;335(26):1933-40.

Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225-37.

Empana J-P, Blom MT, Böttiger BW, et al. Determinants of occurrence and survival after sudden cardiac arrest-a European per- spective: the ESCAPE-NET project. Resuscitation 2018;124:7–13.

Empana J-P, Lerner I, Valentin E, et al. Incidence of sudden cardiac death in the European Union. J Am Coll Cardiol 2022;79:1818–27.

Yan S, Gan Y, Jiang N, et al. The global survival rate among adult out-of-hospital cardiac arrest patients who received cardiopulmonary resuscitation: a systematic review and meta-analysis. Critical care 2020;24:61.

Gräsner J-T, Herlitz J, Tjelmeland IBM, et al. European re- suscitation council guidelines 2021: epidemiology of cardiac arrest in Europe. Resuscitation 2021;161:61–79.

Hallstrom AP, Ornato JP, Weisfeldt M, et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med 2004;351:637–46.

Pollack RA, Brown SP, Rea T, et al. Impact of bystand- er automated external defibrillator use on survival and functional outcomes in shock- able observed public cardiac arrests. Circulation 2018;137:2104–13.

Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996; 17:1390.

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.

Könemann H, Dagres N, Merino JL, et al. Spotlight on the 2022 ESC guideline VIEWPOINT management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects. Europace 2023 May 19;25(5):euad091.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagno- sis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contributi- on of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.

Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacolo- gical Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the Ame- rican College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Ame- rica. J Am Coll Cardiol 2016;68:1476–88.

Myerburg RJ, Castallenos A. Cardiac Arrest and Sudden Cardiac Death. (Braunwald E, Zipes DP, Libby P, Bonow RO.) Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philedelphia: Saunders Elsevier. 933-974, 2008.

Spooner PM, Albert C, Benjamin EJ, et al. Sudden cardiac death, genes, and arrhythmogenesis: consideration of new population and mechanistic approaches from a National Heart, Lung, and Blood Institute workshop, Part II. Circulation. 103:2447-52, 2001.

Bayes de Luna A, Coumel P. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 117:151- 9,1989.

Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine 346.12 (2002): 877-883.

Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. European Heart Journal (2000) 21, 2071–2078.

CASCADE Investigators. Cardiac Arrest in Seattle: Conven- tional versus amiodarone drug evaluation (The CASCADE Study). Am J Cardiol 1991; 67: 578–84.

Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997; 350: 1417–24.

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-83.

Connolly SJ, Gent M, Roberts RS. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-302.

Kuck KH, Cappato R, Siebels J. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-54.

Siebels J, Cappato R, Ruppel R. ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg. Pacing Clin Electrophysiol. 16:552-8, 1993.

Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003; 41:1573.

Chan PS, Hayward RA. Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. J Am Coll Cardiol 2005; 45:1474.

Katz DF, Peterson P, Borne RT, et al. Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement: An Analysis From the NCDR ICD Registry. JACC Clin Electrophysiol 2017; 3:20.

Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J 2007; 28:1746.

Betz JK, Katz DF, Peterson PN, et al. Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. J Am Coll Cardiol 2017; 69:265.

de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. out-of-hospital cardiac arrest in the 1990’s: a population-based study in the maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30:1500–5.

Lynge TH, Risgaard B, Banner J, et al. Nationwide burden of sudden cardiac death: a study of 54,028 deaths in Denmark. Heart Rhythm 2021;18:1657–65.

Moss AJ, Hall WJ, Cannom DS,et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996 Dec 26;335(26):1933-40.

Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan 20;352(3):225-37.

Empana J-P, Blom MT, Böttiger BW, et al. Determinants of occurrence and survival after sudden cardiac arrest-a European per- spective: the ESCAPE-NET project. Resuscitation 2018;124:7–13.

Empana J-P, Lerner I, Valentin E, et al. Incidence of sudden cardiac death in the European Union. J Am Coll Cardiol 2022;79:1818–27.

Yan S, Gan Y, Jiang N, et al. The global survival rate among adult out-of-hospital cardiac arrest patients who received cardiopulmonary resuscitation: a systematic review and meta-analysis. Critical care 2020;24:61.

Gräsner J-T, Herlitz J, Tjelmeland IBM, et al. European re- suscitation council guidelines 2021: epidemiology of cardiac arrest in Europe. Resuscitation 2021;161:61–79.

Hallstrom AP, Ornato JP, Weisfeldt M, et al. Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med 2004;351:637–46.

Pollack RA, Brown SP, Rea T, et al. Impact of bystand- er automated external defibrillator use on survival and functional outcomes in shock- able observed public cardiac arrests. Circulation 2018;137:2104–13.

Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996; 17:1390.

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.

Könemann H, Dagres N, Merino JL, et al. Spotlight on the 2022 ESC guideline VIEWPOINT management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects. Europace 2023 May 19;25(5):euad091.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagno- sis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contributi- on of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.

Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacolo- gical Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the Ame- rican College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Ame- rica. J Am Coll Cardiol 2016;68:1476–88.

Myerburg RJ, Castallenos A. Cardiac Arrest and Sudden Cardiac Death. (Braunwald E, Zipes DP, Libby P, Bonow RO.) Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philedelphia: Saunders Elsevier. 933-974, 2008.

Spooner PM, Albert C, Benjamin EJ, et al. Sudden cardiac death, genes, and arrhythmogenesis: consideration of new population and mechanistic approaches from a National Heart, Lung, and Blood Institute workshop, Part II. Circulation. 103:2447-52, 2001.

Bayes de Luna A, Coumel P. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 117:151- 9,1989.

Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine 346.12 (2002): 877-883.

Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. European Heart Journal (2000) 21, 2071–2078.

CASCADE Investigators. Cardiac Arrest in Seattle: Conven- tional versus amiodarone drug evaluation (The CASCADE Study). Am J Cardiol 1991; 67: 578–84.

Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997; 350: 1417–24.

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-83.

Connolly SJ, Gent M, Roberts RS. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-302.

Kuck KH, Cappato R, Siebels J. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-54.

Siebels J, Cappato R, Ruppel R. ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg. Pacing Clin Electrophysiol. 16:552-8, 1993.

Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003; 41:1573.

Chan PS, Hayward RA. Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new-onset ventricular arrhythmia: an effectiveness study. J Am Coll Cardiol 2005; 45:1474.

Katz DF, Peterson P, Borne RT, et al. Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement: An Analysis From the NCDR ICD Registry. JACC Clin Electrophysiol 2017; 3:20.

Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J 2007; 28:1746.

Betz JK, Katz DF, Peterson PN, et al. Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. J Am Coll Cardiol 2017; 69:265.